Benjamin L. Ebert, President and CEO at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“As Dana-Farber Cancer Institute continues to grow, we are excited to have signed a letter of intent to open a new ambulatory building located at 60 Guest St. in Brighton, Mass., at Boston Landing.
Pending regulatory approval, we aim to open the new practice in summer 2029. The beautiful space will include exam rooms, infusion, pharmacy, radiology, lab services and clinical trials together in one location to deliver multidisciplinary care.
With increasing cancer incidence, more patients are turning to us for their cancer care. As always, their needs remain at the center of everything we do. This additional state-of-the art ambulatory practice will enable us to provide exceptional care to more patients who are counting on us.”
Dana-Farber Cancer Institute has made a post about it as well:
“We are honored to share that the Yawkey Foundation made a generous $50 million grant to support our planned cancer hospital and the Future of Cancer Care Fund. The gift commemorates an eight-decade partnership and will help support construction of our future cancer hospital and other critical priorities including accelerating cancer research, and advancing early detection, survivorship, psychosocial services, and patient assistance.
‘We’re profoundly grateful for the Yawkey Foundation’s visionary generosity,’
– said Benjamin L. Ebert, MD, PhD, president and CEO of Dana-Farber.
‘This grant exemplifies the Yawkey Foundation’s enduring legacy that has made an incredible impact on cancer care and research. Their transformational grant will advance groundbreaking research, innovative treatments, and patient-centered care, while supporting the future cancer hospital at Dana-Farber Cancer Institute.’
To read the full press release, visit the link.”
Other articles featuring Benjamin L. Ebert on OncoDaily.